Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Q-linea AB (publ) (3F8.F)

Compare
0.0020
0.0000
(0.00%)
As of 8:34:56 AM GMT+2. Market Open.
Loading Chart for 3F8.F
  • Previous Close 0.0020
  • Open 0.0020
  • Bid 0.0011 x --
  • Ask 0.0052 x --
  • Day's Range 0.0020 - 0.0020
  • 52 Week Range 0.0001 - 0.3610
  • Volume 77,082
  • Avg. Volume 6,438
  • Market Cap (intraday) 150.984M
  • Beta (5Y Monthly) 1.05
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2600
  • Earnings Date Apr 29, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. The company offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. It serves healthcare providers. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

qlinea.com

94

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 3F8.F

View More

Performance Overview: 3F8.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

3F8.F
89.19%
OMX Stockholm 30 Index (^OMX)
7.65%

1-Year Return

3F8.F
98.59%
OMX Stockholm 30 Index (^OMX)
9.07%

3-Year Return

3F8.F
99.97%
OMX Stockholm 30 Index (^OMX)
7.33%

5-Year Return

3F8.F
99.96%
OMX Stockholm 30 Index (^OMX)
63.25%

Compare To: 3F8.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3F8.F

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    150.98M

  • Enterprise Value

    276.52M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.70

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    117.07

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -69.75%

  • Return on Equity (ttm)

    -267.45%

  • Revenue (ttm)

    5.79M

  • Net Income Avi to Common (ttm)

    -216.87M

  • Diluted EPS (ttm)

    -0.2600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    25.66M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -105.48M

Research Analysis: 3F8.F

View More

Company Insights: 3F8.F

Research Reports: 3F8.F

View More

People Also Watch